| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/30/2023 | 795.52% | HC Wainwright & Co. | → $12 | Reiterates | → Buy |
| 10/24/2022 | 795.52% | HC Wainwright & Co. | $18 → $12 | Maintains | Buy |
| 10/20/2022 | 49.25% | SVB Leerink | $7 → $2 | Maintains | Market Perform |
| 10/20/2022 | 1243.28% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
| 09/09/2022 | 347.76% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 07/05/2022 | 497.01% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 07/01/2022 | 422.39% | SVB Leerink | $21 → $7 | Downgrades | Outperform → Market Perform |
| 05/24/2022 | 1392.54% | Morgan Stanley | $21 → $20 | Maintains | Overweight |
| 05/13/2022 | 1467.16% | SVB Leerink | $22 → $21 | Maintains | Outperform |
| 03/23/2022 | 1467.16% | Morgan Stanley | $20 → $21 | Maintains | Overweight |
| 11/12/2021 | 1541.79% | SVB Leerink | $21 → $22 | Maintains | Outperform |
| 06/01/2021 | 2511.94% | Morgan Stanley | → $35 | Initiates Coverage On | → Overweight |
| 06/01/2021 | 1840.3% | Guggenheim | → $26 | Initiates Coverage On | → Buy |
| 06/01/2021 | 2511.94% | Evercore ISI Group | → $35 | Initiates Coverage On | → Outperform |
| 06/01/2021 | 1467.16% | SVB Leerink | → $21 | Initiates Coverage On | → Outperform |
What is the target price for Talaris Therapeutics (TALS)?
The latest price target for Talaris Therapeutics (NASDAQ: TALS) was reported by HC Wainwright & Co. on January 30, 2023. The analyst firm set a price target for $12.00 expecting TALS to rise to within 12 months (a possible 795.52% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Talaris Therapeutics (TALS)?
The latest analyst rating for Talaris Therapeutics (NASDAQ: TALS) was provided by HC Wainwright & Co., and Talaris Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Talaris Therapeutics (TALS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Talaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Talaris Therapeutics was filed on January 30, 2023 so you should expect the next rating to be made available sometime around January 30, 2024.
Is the Analyst Rating Talaris Therapeutics (TALS) correct?
While ratings are subjective and will change, the latest Talaris Therapeutics (TALS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Talaris Therapeutics (TALS) is trading at is $1.34, which is within the analyst's predicted range.